title: [Impact of preoperative therapy with 5-α-reductase inhibitors in the treatment of benign prostatic hyperplasia].
abstract: Benign prostatic hyperplasia is considered a progressive disease intimately linked with aging. The long-term use of combination therapy with a 5-alpha-reductase inhibitor, together with an alpha blocker in men with moderate-severe symptoms, reduces the risk of clinical progression and BPH-related surgery. It is unclear what the impact is of preoperative therapy with 5-ARI in patients that undergo surgery. The aim of our study was to evaluate the impact of preoperative therapy with 5-alpha-reductase inhibitors on: a) indication on the type of surgery; b) surgical and functional outcomes; c) surgical complications. This is a prospective observational study. It will include all patients undergoing surgery by TURP or Open Prostatectomy in a period of 24 months. We expect results that demonstrate significant and favorable influence of pretreatment with 5-alpha-reductase inhibitors on certain outcomes. Therefore, therapy with 5-ARI could be considered as neoadjuvant to surgery, whatever this is.
authors.affiliation: Clinica urologica, Università Federico II, Napoli, Italy. giacomo.destefano@libero.it
authors.forename: Giacomo
authors.initials: G
authors.lastname: De Stefano
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Fusco
authors.forename: Davide
authors.initials: D
authors.lastname: Arcaniolo
authors.forename: Antonio
authors.initials: A
authors.lastname: Pistone
authors.forename: Marco
authors.initials: M
authors.lastname: Capece
authors.forename: Simone
authors.initials: S
authors.lastname: Sannino
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mirone
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D011446:Prospective Studies; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery; D012107:Research Design; D020728:Transurethral Resection of Prostate
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists